February 16, 2026

FDA issues complete response letter to Disc Medicine’s bitopertin NDA

By Salong Debbarma

The submission sought accelerated approval and was part of the FDA Commissioner’s National Priority Voucher pilot programme. The CRL for bitopertin EPP affects the regulatory pathway and potential